大分割立体定向放疗治疗寡转移性乳腺癌:部分患者生存超过十年
前瞻性II期方案纳入48例有1-5个颅外寡转移灶的乳腺癌女性,全部接受大分割立体定向放疗。仅骨寡转移患者5年与10年总生存率分别为83%和75%,非骨寡转移患者分别为31%和17%(p=0.002)。作者认为肿瘤负荷(体积与病灶数)似乎影响复发风险,需进一步研究识别最可能获益的患者。
要点
- 48例乳腺癌颅外寡转移(1-5个病灶)患者接受大分割立体定向放疗,部分生存超过10年。
- 仅骨寡转移患者5年与10年总生存率分别为83%和75%,非骨寡转移患者分别为31%和17%(p=0.002)。
- 非骨寡转移患者中,寡转移灶净GTV>25 cc与无局部复发(p=0.047)和无广泛转移生存(p=0.028)显著相关。
核心结论
- 部分接受大分割立体定向放疗的乳腺癌寡转移患者可生存超过10年。
- 肿瘤负荷(体积和病灶数量)似乎影响复发风险。
- 需要进一步研究以更好地识别最可能从转移灶定向放疗中获益的乳腺癌患者。
研究设计与样本
- 前瞻性II期方案,纳入48例有1-5个颅外寡转移灶的乳腺癌女性患者。
- 对所有影像学可见病灶行大分割立体定向放疗,采用多种剂量分割方案。
- 多数患者(n=27)接受10次每日照射,其中通常≥50 Gy者17例。
主要发现
- 仅骨寡转移患者(n=12)较非仅骨寡转移患者(n=36)显著更年轻、更常见在原发乳腺癌诊断时即出现寡转移(即同时性)、且激素受体阳性疾病显著更多。
- 大分割立体定向放疗后5年和10年总生存率:仅骨寡转移患者分别为83%和75%,非仅骨寡转移患者分别为31%和17%(p=0.002)。
- 仅骨寡转移患者无广泛转移生存显著更优(p=0.018)。
- 非仅骨寡转移患者中,寡转移灶净GTV>25 cc是无局部复发的显著因素(p=0.047),也是无广泛转移生存的显著因素(p=0.028)。
- 非仅骨寡转移患者中,寡转移病灶数量(p=0.007)和受累器官数量(p=0.001)也是无广泛转移生存的显著因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究以更好地识别最可能从转移灶定向放疗中获益的乳腺癌患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical state of oligometastases describes metastases limited in number and extent, amenable to metastasis-directed therapy. We sought to analyze long-term outcomes and characterize potential prognostic factors, in women with breast cancer (BC) oligometastases treated with hypofractionated stereotactic radiation (HSRT) therapy on a prospective phase II protocol. METHODS: Forty-eight women with 1-5 extracranial BC oligometastases received HSRT to all radiographically apparent sites of disease. Various dose-fractionation schedules were used. Most (n = 27) received 10 daily fractions, typically ≥50 Gy (n = 17). RESULTS: BC patients with bone-only oligometastases (BO, n = 12) vs. all other patients (non-BO; n = 36) were significantly younger, more likely to present with oligometastases at the time of primary BC diagnosis (i.e., synchronous), and significantly more likely to have had hormone receptor-positive disease. The 5-year and 10-year overall survival (OS) rates after HSRT were 83% and 75%, respectively, for BO patients vs. 31% and 17%, respectively, for non-BO patients (p = 0.002). BO patients experienced a significantly (p = 0.018) greater freedom from widespread metastases (FFWM). Among non-BO patients, net oligometastatic GTV >25 cc (reflecting disease burden) was a significant factor for freedom from local recurrence (p = 0.047) and FFWM (p = 0.028). The number of oligometastatic lesions (p = 0.007) and organs (p = 0.001) involved were also significant factors for FFWM in non-BO patients. CONCLUSIONS: Some patients with BC oligometastases treated with HSRT can survive >10 years. Tumor burden (volume and number of lesions) appears to impact risk of recurrence. Further research is needed to help better identify BC patients most likely to benefit from metastasis-directed radiotherapy.
引用
- Milano MT, Katz AW, Zhang H, et al. Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: Some patients survive longer than a decade. Radiother Oncol. 2018. PMID: 30773186. doi:10.1016/j.radonc.2018.11.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。